These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
123 related items for PubMed ID: 20663675
1. 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models. Cheng Z, Chen AF, Wu F, Sheng L, Zhang HK, Gu M, Li YY, Zhang LN, Hu LH, Li JY, Li J. Bioorg Med Chem; 2010 Aug 15; 18(16):5915-24. PubMed ID: 20663675 [Abstract] [Full Text] [Related]
2. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H, Taketo MM, Cooney GJ, Kraegen EW, James DE, Hu LH, Li J, Ye JM. Diabetes; 2008 May 15; 57(5):1414-8. PubMed ID: 18285556 [Abstract] [Full Text] [Related]
3. Berberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein efflux. Shan YQ, Ren G, Wang YX, Pang J, Zhao ZY, Yao J, You XF, Si SY, Song DQ, Kong WJ, Jiang JD. Metabolism; 2013 Mar 15; 62(3):446-56. PubMed ID: 23079743 [Abstract] [Full Text] [Related]
4. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, Oh GT, Park HS, Lee KU, Lane MD, Kim JB. Am J Physiol Endocrinol Metab; 2009 Apr 15; 296(4):E812-9. PubMed ID: 19176354 [Abstract] [Full Text] [Related]
5. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, Wang SK, Zhou ZX, Song DQ, Wang YM, Pan HN, Kong WJ, Jiang JD. Metabolism; 2010 Feb 15; 59(2):285-92. PubMed ID: 19800084 [Abstract] [Full Text] [Related]
6. Berberine derivatives reduce atherosclerotic plaque size and vulnerability in apoE(-/-) mice. Chen J, Cao J, Fang L, Liu B, Zhou Q, Sun Y, Wang Y, Li Y, Meng S. J Transl Med; 2014 Nov 26; 12():326. PubMed ID: 25425200 [Abstract] [Full Text] [Related]
7. Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions. Chen Y, Li Y, Wang Y, Wen Y, Sun C. Metabolism; 2009 Dec 26; 58(12):1694-702. PubMed ID: 19767038 [Abstract] [Full Text] [Related]
8. Preparation of an anhydrous reverse micelle delivery system to enhance oral bioavailability and anti-diabetic efficacy of berberine. Wang T, Wang N, Song H, Xi X, Wang J, Hao A, Li T. Eur J Pharm Sci; 2011 Sep 18; 44(1-2):127-35. PubMed ID: 21742030 [Abstract] [Full Text] [Related]
9. Transforming berberine into its intestine-absorbable form by the gut microbiota. Feng R, Shou JW, Zhao ZX, He CY, Ma C, Huang M, Fu J, Tan XS, Li XY, Wen BY, Chen X, Yang XY, Ren G, Lin Y, Chen Y, You XF, Wang Y, Jiang JD. Sci Rep; 2015 Jul 15; 5():12155. PubMed ID: 26174047 [Abstract] [Full Text] [Related]
10. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice. Anandharajan R, Sayyed SG, Doshi LS, Dixit P, Chandak PG, Dixit AV, Brahma MK, Deshmukh NJ, Gupte R, Damre A, Suthar J, Padigaru M, Sharma SD, Nemmani KV. Metabolism; 2009 Oct 15; 58(10):1503-16. PubMed ID: 19608207 [Abstract] [Full Text] [Related]
11. Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. Xue M, Yang MX, Zhang W, Li XM, Gao DH, Ou ZM, Li ZP, Liu SH, Li XJ, Yang SY. Int J Nanomedicine; 2013 Oct 15; 8():4677-87. PubMed ID: 24353417 [Abstract] [Full Text] [Related]
12. Hypoglycemic and hypolipidemic effects of processed Aloe vera gel in a mouse model of non-insulin-dependent diabetes mellitus. Kim K, Kim H, Kwon J, Lee S, Kong H, Im SA, Lee YH, Lee YR, Oh ST, Jo TH, Park YI, Lee CK, Kim K. Phytomedicine; 2009 Sep 15; 16(9):856-63. PubMed ID: 19303272 [Abstract] [Full Text] [Related]
13. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo. Kim MK, Chae YN, Son MH, Kim SH, Kim JK, Moon HS, Park CS, Bae MH, Kim E, Han T, Choi HH, Shin YA, Ahn BN, Lee CH, Lim JI, Shin CY. Eur J Pharmacol; 2008 Oct 24; 595(1-3):119-25. PubMed ID: 18727927 [Abstract] [Full Text] [Related]
14. MgAl monolayer hydrotalcite increases the hypoglycemic effect of berberine by enhancing its oral bioavailability. Wang A, Yang W, Yang X, Mei X, Hu T, Liang R, Meng D, Yan D. Biomed Pharmacother; 2020 Jul 24; 127():110140. PubMed ID: 32380387 [Abstract] [Full Text] [Related]
20. Biological activity of AC3174, a peptide analog of exendin-4. Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA, Gedulin BR, Flanagan SD, Jodka CM, Hoyt JA, McCowen KM, Parkes DG, Anderson CM. Regul Pept; 2007 Jun 07; 141(1-3):113-9. PubMed ID: 17292977 [Abstract] [Full Text] [Related] Page: [Next] [New Search]